0001209191-22-047903.txt : 20220829 0001209191-22-047903.hdr.sgml : 20220829 20220829174610 ACCESSION NUMBER: 0001209191-22-047903 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220825 FILED AS OF DATE: 20220829 DATE AS OF CHANGE: 20220829 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GUGGENHIME ANDREW CENTRAL INDEX KEY: 0001230724 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 221212286 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-25 0 0001649094 Vaxcyte, Inc. PCVX 0001230724 GUGGENHIME ANDREW C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 0 1 0 0 President and CFO Common Stock 2022-08-25 4 M 0 17052 5.35 A 59239 D Common Stock 2022-08-25 4 S 0 17052 28.00 D 42187 D Common Stock 2022-08-26 4 M 0 1295 5.35 A 43482 D Common Stock 2022-08-26 4 S 0 1295 28.00 D 42187 D Common Stock 2022-08-29 4 M 0 17653 5.35 A 59840 D Common Stock 2022-08-29 4 S 0 17653 28.00 D 42187 D Stock Option (right to buy) 5.35 2022-08-25 4 M 0 17052 0.00 D 2030-05-11 Common Stock 17052 476566 D Stock Option (right to buy) 5.35 2022-08-26 4 M 0 1295 0.00 D 2030-05-11 Common Stock 1295 475271 D Stock Option (right to buy) 5.35 2022-08-29 4 M 0 17653 0.00 D 2030-05-11 Common Stock 17653 457618 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact 2022-08-29